1. Ammassari A et al. (2001). Self-reported symptoms and medication side-effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28(5):445-449.
2. Anderson W, Weatherburn P. Taking heart? The impact of combination therapy on the lives of people with HIV (phase 2). London, Syria Research, 1999.
3. Bangsberg DR et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14:357-366.
4. Brigido LFM et al. (1998). Low adherence in antiretroviral users at Sao Paulo, Brazil. 12th World AIDS Conference, Geneva, 28 June-3 July 1998. Abstract no. 32370.
5. Byakika-Tusiime J et al. (2003). Ability to purchase and secure stable therapy are significant predictors of non-adherence to antiretroviral therapy in Kampala, Uganda. 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA. 10-14 February 2003. Abstract no. 170.
6. Carr A (2002). Improvement of the study, analysis and reporting of adverse events associated with antiretroviral therapy. Lancet, 360:81-85
7. Carr A, Cooper DA (2000). Adverse effects of antiretroviral therapy. Lancet, 356: 1423-30.
8. Carter M. Adherence - information series for HIV-positive people. 2nd ed. London, NAM, 2004.
9. Carrieri P, Caillefon V, Le moing V (2002). The dynamic of adherence to Highly Active Antiretroviral Therapy: Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes, 28:232-9.
10. Chesney MA (2000). Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases, 30(Suppl 2):S171-6.
11. Chesney MA, Morin M, Sherr L (2000). Adherence to HIV combination therapy. Social Science & Medicine, 50:1599-1605.
12. Chesney MA et al. (1999). Adherence: a necessity for successful HIV combination therapy. AIDS, 13(Suppl A):5271-5278.
13. Daniel OJ et al. (2004). Adherence pattern to ARV drugs among AIDS patients on self- purchased drugs and those on free medications in Sagamu, Nigeria. XV International AIDS Conference. Bangkok, Thailand. 30 March - 2 April 2004.
14. Darder M et al. (2004). Determinants of short and long-term adherence to antiretroviral treatment in resource-poor settings. XV International AIDS Conference. Bangkok, Thailand. 30 March - 2 April 2004. Abstract no. B11852.
15. Eldred I J, Wu Aw, Chaisson RE (1998). Adherence to antiretroviral and pneumocystic prophylaxis in HIV disease. Journal Acquired Immune Deficiency Syndromes, 18:117.
16. Ferris DC et al. (2004). Self-reported adherence to antiretroviral therapy and virologic outcomes in HIV-infected persons in Durban, KwaZulu Natal, South Africa. XV International AIDS Conference. Bangkok, Thailand. 30 March - 2 April 2004. Abstract no. WePeB5829.
17. Fischl M, Rodriguez A, Scerpella E. (2000). Impact of directly observed therapy on outcomes in HIV clinical trials. 7th Conference on Retro viruses and Opportunistic Infections, San Francisco, USA. 30 January - 2 February 2000. Abstract no. 71.
18. Gill CJ et al (2005). No complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS, 19:1243-1249.
19. Gillford AL et al. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal Acquired Immune Deficiency Syndrome, 23(5):386-95.
20. Golin CE et al. (2002). A prospective study of predictors of adherence to combination antiretroviral medication. Journal of General Internal Medicine, 17:756-765.
21. Government through Presidential Directive CAB: 35/93,17th November 1993. Gaborone. (UNDP, 2001) Botswana human development report, 2000, p.41-42.
22. Harries AD, et al. (2001). Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet, 358:410-414.
23. Horne R. Adherence to medication, a review of existing research. In: Myers L, Midence K (eds.). Adherence to treatment in medical conditions (pp.285-310). London, Harwood Academic, 1998.
24. Horne R. Compliance, adherence and concordance. In: Taylor K and Harding G (eds.), Pharmacy practice (pp.165-184). London, Taylor & Francis, 2001.
25. KITSO. Harvard Institute HIV/AIDS. KITSO training manual for health workers in Botswana, 2004
26. Klitzman RL et al. (2004). Intricacies and inter-relationships between disclosure and HAART: a qualitative study. AIDS Care, 16(5):628-640.
27. Kumarasamy N et al.(2005). Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: A qualitative study. AIDS Patient Care and STDs, 19(8):526-537.
28. Lerner BH, Gulick R M, Dubler NN. Rethinking non-adherence: historical perspectives on triple-drug therapy for HIV disease. Annals of Internal Medicine, 1998, 129(7):573-578.
29. Liu H, et al. (2001). A comparison of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134:968-997.
30. Machtinger E, Bangsberg DR (2005). Adherence to HIV antiretroviral therapy. Available at: http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09
31. Muganzi AM et al. (2004). Adherence to HAART in a rural resource limited country HIV/AIDS treatment programme: the experience of Arua Anti-Retroviral (ARV) Treatment Programme-Uganda. XV International AIDS Conference. Bangkok, Thailand. 30 March - 2 April 2004. Abstract no.: WePeB5760.
32. Murphy DA et al. (2004). Predictors of antiretroviral adherence. AIDS Care, 16(4): 471-484.
33. National AIDS Coordinating Agency (NACA). Botswana sentinel year book 2003. Available at: http://www.naca.gov.bw/about.htm.
34. National AIDS Coordinating Agency (NACA) website: http://www.naca.gov.bw
35. Nemes MIB, Carvalho HB, Souza MFM (2004). Antiretroviral therapy adherence in Brazil. AIDS 18(Suppl 3):S15-S20.
36. Nwokike J (2004). Baseline data and predictors of adherence in patients on antiretroviral therapy in Maun General Hospital, Botswana. International Conference on Improving Use of Medicines (ICIUM). Bangkok, Thailand. Abstract no. HI012, 2004.
37. Ormazu JA (2000). Disclosure decision model: determining how and when individuals will self-disclose. Personality and Social Psychology Review, 4:174-185.
38. Omes C et al. (2004). Adherence to antiretroviral (ARV) therapy among advanced-stage, indigent patients in the funded ESTHER programme in Kigali, Rwanda. XV International AIDS Conference. Bangkok, Thailand. 30 March - 2 April 2004. Abstract no. B12315.
39. Orrell C, Bangberg DR, Badri M, Wood R (2003). Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS, 17:1369-1375.
40. Palella FJ Jr et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338:853-860.
41. Paterson DL et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1):21-30.
42. Perelson AS, Neumann AU, Markowitz M (1996). HIV-1 Dynamics in viro; viron clearance rate, infected cell life span, and viral generation time. Science, 271(5255): 1582-6.
43. Poppa A et al. Guidelines on provision of adherence support to individuals receiving antiretroviral therapy. London, British HIV Association/British Association for Sexual Health and HIV, 1993.
44. Ramotlhwa (2005). ARV statistics. (Personal communication).
45. Reiter GS et al. (2000). Elements of success in HIV clinical care. Topics in HIV Medicine 8:67.
46. Safren SA et al. (2005). ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care, 17(7):853-862.
47. Singh N et al. (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care, 8:261-269.
48. Stevens W, Kaye S, Corrah T (2004). Education and debate: antiretroviral therapy in Africa. British Medical Journal, 328:280-2.
49. Tuldra A, Fumaz C R, Ferrer MJ (2000). Prospective randomized two arm controlled study to determine the efficacy of a specific intervention to improve long term adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 25:221-8.
50. Turner BJ (2002). Adherence to antiretroviral therapy by Human Immunodeficiency Virus-Infected Patients. Journal of Infectious Diseases, 185(Suppl 2):S143-51.
51. UNAIDS/WHO (2005). The AIDS epidemic update - Special report on HIV prevention. Available at: http://www.who.int/hiv/epiupdate2005/en/.
52. Vitolins MZ et al. (2000). Measuring adherence to behavioral and medical interventions. Controlled Clinical Trials; 21:188S-194S.
53. Weiser S et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal Acquired Immune Deficiency Syndrome, 34:281- 288.
54. WHO. Progress on global access to HIV antiretroviral therapy. A report on "3 by 5" and beyond. Geneva, World Health Organization, 2006.
55. Zea et al. (2005). Disclosure of HIV status and psychological well-being Among Latino gay and bisexual men. AIDS and Behavior, 9(1): 15-26.